Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Non-Current Assets (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Other Non-Current Assets for 4 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 1.92% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.9 million, a 1.92% increase, with the full-year FY2025 number at $2.9 million, up 1.92% from a year prior.
  • Other Non-Current Assets was $2.9 million for Q4 2025 at Phathom Pharmaceuticals, up from $2.9 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $3.7 million in Q2 2023 to a low of $299000.0 in Q4 2022.
  • A 4-year average of $1.9 million and a median of $1.7 million in 2025 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: tumbled 62.86% in 2023, then soared 858.86% in 2024.
  • Phathom Pharmaceuticals' Other Non-Current Assets stood at $299000.0 in 2022, then surged by 465.89% to $1.7 million in 2023, then surged by 69.15% to $2.9 million in 2024, then grew by 1.92% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Other Non-Current Assets are $2.9 million (Q4 2025), $2.9 million (Q3 2025), and $1.7 million (Q2 2025).